PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital _June 30, 2022.
                 Monthly information related to total number of voting rights and shares composing the share capital _ June 3 0 , 202 2 . Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C -
View HTML
Toggle Summary Report – ERYTECH’s Combined Shareholders’ Meeting On June 24, 2022
REPORT – ERYTECH ’S COMBINED SHAREHOLDERS’ MEETING ON JUNE 2 4 , 20 22 Cambridge, MA (U.S.) and Lyon (France), June 24 , 2022 – ERYTECH Pharma ( Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital _May 31, 2022.
                 Monthly information related to total number of voting rights and shares composing the share capital _May 3 1 , 202 2 . Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN
View HTML
Toggle Summary ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 24, 2022
ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 2 4 , 20 22 Cambridge, MA (U.S.) and Lyon (France), May 24 , 2022 – ERYTECH Pharma ( Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by
View HTML
Toggle Summary ERYTECH to Present at the H.C. Wainwright Global Investment Conference
ERYTECH to P resent at the H.C. Wainwright Global Investment Conference Cambridge, MA (U.S.) and Lyon (France), May 1 7 , 2022 – ERYTECH Pharma ( Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2022
                 Monthly information related to total number of voting rights and shares composing the share capital – April 30 , 202 2 . Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C -
View HTML
Toggle Summary ERYTECH Provides Business and Financial Update for the First Quarter of 2022
ERYTECH Provides Business and Financial Update for the First Quarter of 20 2 2 Conference call and webcast on Friday, May 13, 2022 at 8:30am EDT / 02:30pm CEST          U.S. cell therapy manufacturing facility sold to Catalent for a total consideration of USD 44.5 million Progress towards seeking
View HTML
Toggle Summary ERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report on Form 20-F, as well as its 2022 financial calendar
ERYTECH Announces Filing of 202 1 Universal Registration Document and 202 1 Annual Report on Form 20-F , as well as its 2022 financial calendar Cambridge, MA (U.S.) and Lyon (France), April 28 , 202 2 – ERYTECH Pharma (Euronext Paris : ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical
View HTML
Toggle Summary ERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with Catalent
         ERYTECH Sell s U. S. Manufacturing Facility and Enter s Long-Term Supply Agreement with Catalent Catalent a cquire d ERYTECH’s U.S. c ell t herapy m anufacturing f acility for a t otal c onsideration of USD 44.5 m illion ERYTECH and Catalent to e nter into a l ong- t erm s upply a greement
View HTML
Toggle Summary ERYTECH Announces Publication of Positive Results from Eryaspase Phase 2 Trial in Hypersensitive ALL in the British Journal of Haematology
ERYTECH Announces Publication of Positive Results from Eryaspase Phase 2 Trial in Hypersensitive ALL in the British Journal of Haematology The study confirms the potential of eryaspase (GRASPA®) as an attractive treatment option f or acute lymphoblastic leukemia (ALL ) patients with
View HTML
Top